Maple Syrup Urine Disease (MSUD) Animal Model Service
Maple syrup urine disease (MSUD) is a rare autosomal recessive neurometabolic disorder caused by deficient activity of the branched-chain α-ketoacid dehydrogenase (BCKDH) complex, resulting in toxic accumulation of branched-chain amino acids (BCAAs), leucine, isoleucine, and valine, along with their corresponding branched-chain ketoacids (BCKAs). Accelerate your preclinical therapeutic development for MSUD with our comprehensive, turnkey animal model development and evaluation services. Leveraging cutting-edge genetic engineering and precise phenotypic validation, Protheragen delivers highly translational MSUD rodent models tailored to your specific drug discovery goals, from small molecule screening to gene therapy evaluation.
Overview of Maple Syrup Urine Disease (MSUD) Animal Models
Maple syrup urine disease (MSUD) is an inborn error of metabolism arising from biallelic mutations in genes encoding subunits of the mitochondrial BCKDH complex, specifically BCKDHA (E1α), BCKDHB (E1β), or DBT (dihydrolipoamide branched-chain transacylase). This enzyme complex catalyzes the oxidative decarboxylation of BCKAs derived from leucine, isoleucine, and valine, the committed and rate-limiting step in BCAA catabolism. Enzyme deficiency leads to systemic accumulation of BCAAs and BCKAs in plasma and tissues, with leucine and its corresponding ketoacid α-ketoisocaproate (α-KIC) exerting particularly potent neurotoxic effects through mechanisms including neurotransmitter depletion (e.g., glutamate and glutamine dysregulation), cerebral energy impairment, oxidative stress, and neuroinflammation.
Fig.1 AAV-based gene therapy reverses the maple syrup urine disease phenotype in affected mice. (Greig, J. A., et al., 2021)
MSUD is classified into several phenotypes: the severe classic neonatal-onset form, milder intermittent, intermediate, and thiamine-responsive variants. Classic MSUD presents within the first days of life with poor feeding, vomiting, lethargy, progressive encephalopathy, and the characteristic maple syrup odor in cerumen and urine. Without prompt dietary management or liver transplantation, affected individuals face high risk of recurrent metabolic crises, cerebral edema, and irreversible neurological damage.
Animal models that recapitulate the biochemical, neurological, and clinical features of MSUD are indispensable for understanding disease pathogenesis, identifying biomarkers, and enabling rigorous preclinical evaluation of investigational therapies. Rodent models, particularly mice, have emerged as the predominant platform due to their well-characterized genetics, amenability to precise genome engineering, and established behavioral and metabolic phenotyping paradigms.
Our Services
Drawing on extensive expertise in genetic engineering, precision metabolic phenotyping, and translational pharmacology, Protheragen provides comprehensive, custom MSUD animal model services spanning the entire preclinical development continuum, from de novo model generation and multi-platform characterization through rigorous efficacy assessment and regulatory-compliant safety studies, all integrated to streamline your drug development timeline and accelerate translational milestones.
Animal Models of Maple Syrup Urine Disease (MSUD)
Protheragen provides custom development services for a wide range of MSUD animal models tailored to your specific research questions, from severe neonatal-lethal phenotypes to milder chronic or conditional variants. Leveraging advanced genetic engineering platforms, we generate models precisely designed to recapitulate human MSUD genotypes and metabolic derangements, enabling rigorous preclinical evaluation of gene therapy, small molecules, dietary interventions, and other therapeutic modalities.
We offer comprehensive capabilities for generating genetically defined MSUD models through precise genome modification. These include complete loss-of-function knockouts, hypomorphic alleles retaining partial BCKDH activity, humanized knock-in lines carrying patient-derived mutations, tissue-specific conditional knockouts, and transgenic rescue or reporter systems.
- BCKDHA knockout model
- BCKDHB knockout model
- DBT knockout model
- And more
Mouse Model for Maple Syrup Urine Disease (MSUD) Research
| Model Name | Modeling Method | Detailed Description |
|---|---|---|
| Bckdhb-KO Mouse Model | Knockout | To establish the Bckdhb knockout mouse line, exons 4 and 5 of the Bckdhb gene were selectively removed, thereby abolishing expression of the E1β subunit of the BCKDH complex. |
| Bckdha-KO Mouse Model | Knockout | A complete knockout of the Bckdha gene was generated by excising exons 2 through 4, eliminating the coding sequence for the E1α subunit of the BCKDH complex. |
| Dbt-KO Mouse Model | Knockout | Deletion of exon 2 of the Dbt gene was performed to generate Dbt knockout mice, disrupting the E2 subunit of the branched-chain α-ketoacid dehydrogenase complex. |
| Ppm1k-KO Mouse Model | Knockout | Targeted disruption of the Ppm1k gene was achieved by deleting exon 3, resulting in a constitutive knockout mouse model. |
| … | … | … |
Case Study-Bckdhb-KO Mouse Model Development
Model Introduction
The Bckdhb-knockout (Bckdhb-KO) mouse model is a complete loss-of-function system targeting the E1β subunit of the branched-chain α-ketoacid dehydrogenase (BCKDH) complex. Disruption of the Bckdhb gene abolishes BCKDH enzymatic activity, leading to pathological accumulation of branched-chain amino acids (BCAAs) and the MSUD-specific biomarker alloisoleucine, while reducing circulating alanine levels. This model faithfully recapitulates the severe neonatal-onset form of human Maple Syrup Urine Disease (MSUD) type 1B, providing a robust platform for evaluating gene replacement, enzyme therapy, and metabolic modulators.
Methodology
- Animal Model: Homozygous Bckdhb knockout mice were generated via targeted disruption of the Bckdhb gene using standard homologous recombination techniques. Neonatal pups were monitored daily for survival, body weight, and general physical condition through the first two postnatal weeks.
- Phenotypic Analysis Methods: Blood samples were collected from postnatal day 5 pups for quantification of plasma amino acids, including branched-chain amino acids (BCAAs), alloisoleucine, and alanine, using standard chromatography-based methods. Tissue specimens (liver, heart, and brain) were harvested for molecular and biochemical analyses. Quantitative real-time PCR was performed to assess Bckdhb mRNA transcript levels relative to the housekeeping gene Gapdh. Western blotting was used to evaluate BCKDHB protein expression in the same tissues. BCKDH enzyme activity was measured in liver homogenates using a radiolabeled substrate assay.
Phenotypic Analysis & Results
All Bckdhb-KO pups died before the end of the first postnatal week, demonstrating a severe early-onset lethal phenotype. Plasma biochemical profiling revealed marked elevations of BCAAs and alloisoleucine in Bckdhb-KO mice, accompanied by decreased alanine concentrations. Consequently, the leucine-to-alanine ratio was substantially increased, mirroring the metabolic signature documented in human MSUD patients. Molecular analyses confirmed the absence of functional Bckdhb expression in knockout animals. Transcript levels of Bckdhb mRNA were significantly reduced in heterozygous mice across all examined tissues and were barely detectable in Bckdhb-KO mice. Western blot analysis demonstrated absence of BCKDHB protein in the liver, heart, and brain of homozygous knockout animals. Consistent with these findings, BCKDH enzymatic activity was undetectable in liver homogenates from Bckdhb-KO mice. Collectively, these results confirmed that the Bckdhb-KO mouse represents a true null model, exhibiting clinical and biochemical features that faithfully recapitulate the severe neonatal human MSUD phenotype.
Fig.2 Relative Bckdhb mRNA expression normalized to Gapdh in liver, heart, and brain tissues across the WT and Bckdhb-KO mice. Data are presented as mean ± SEM (n=5; ***p < 0.001).
Conclusion
These results demonstrated that constitutive disruption of the Bckdhb gene produces a severe, neonatal-lethal MSUD phenotype in mice, characterized by undetectable BCKDH activity, absence of BCKDHB protein, pathological accumulation of BCAAs and alloisoleucine, and early postnatal mortality. The Bckdhb-KO mouse model therefore serves as a highly reliable preclinical platform for evaluating gene therapy, protein replacement, and other emerging treatments for classic MSUD type 1B, enabling robust assessment of therapeutic efficacy and safety prior to clinical translation. Importantly, survival endpoints, plasma amino acid normalization, and neurobehavioral rescue can be quantified in this model to benchmark candidate interventions.
Contact Us
From custom model generation via advanced genetic engineering platforms to full-spectrum preclinical evaluation, Protheragen provides integrated solutions including comprehensive phenotypic characterization (metabolic profiling, neurological and behavioral assessment, histopathology, and biomarker identification), rigorous pharmacokinetic and pharmacodynamic efficacy studies, and drug safety evaluations (general toxicology, safety pharmacology, and reproductive/developmental toxicity studies) conducted in compliance with regulatory standards to support first-in-human trials. Our scientific team offers end-to-end project support, including study design consultation, timeline optimization, and regulatory document preparation. For project inquiries, custom quotations, or expert consultation on model selection and study design, please contact our scientific team.
Reference
- Greig, Jenny A et al. "Muscle-directed AAV gene therapy rescues the maple syrup urine disease phenotype in a mouse model." Molecular genetics and metabolism 134.1-2 (2021): 139-146.
All of our services and products are intended for preclinical research use only and cannot be used to diagnose, treat or manage patients.